Celluris was selected as a finalist in the Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026, one of the most relevant international competitions for technology-based startups.This achievement highlights the potential of Brazilian biotechnology in an increasingly competitive global landscape. The selection places the company among a select group of innovative organizations that will have the opportunity to present their solutions to investors, research centers, corporations, and leaders from the technology ecosystem of China’s Greater Bay Area.
Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026
The Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026 is an initiative promoted by the Government of the Macao Special Administrative Region. Its goal is to connect innovative startups with investors, innovation centers, and strategic partners in China and the Guangdong-Hong Kong-Macao Greater Bay Area.Since its creation, the competition has connected technology companies from Portuguese-speaking countries with China’s innovation ecosystem. In doing so, it promotes technology exchange, international expansion, and business development opportunities.In addition to financial awards, finalist startups gain international visibility and access to one of the world’s most dynamic regions for science, technology, and investment.
The global relevance of the competition
China’s Greater Bay Area brings together some of the world’s most innovative cities, including Shenzhen, Hong Kong, Guangzhou, and Macao. Together, these cities form one of the world’s largest hubs for technology, research, and entrepreneurship.For this reason, the Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026 has become an important platform for startups seeking to expand their international presence.Participants are evaluated by experts from different fields. The judging committee typically includes investors, researchers, representatives from financial institutions, and leaders of technology incubators.Consequently, reaching the final stage represents significant recognition of the selected companies’ capacity for innovation.
Celluris among the startups selected to represent Brazil
Following a selection process conducted by Traciona together with the competition organizers, only two startups were chosen to represent Brazil in the 2026 edition: Celluris and Massima.This selection demonstrates the strength of Brazilian science and reinforces Celluris’ position as one of the most promising companies in the biotechnology sector.In addition, the selection recognizes the company’s work in developing advanced solutions for cancer treatment through personalized cell therapy.Participating in the final gives Celluris direct access to potential international partners. Likewise, it expands opportunities for scientific and technological collaboration in strategic markets.
The company
Celluris holds a unique position in the Latin American biotechnology landscape. The company is a pioneer in developing personalized treatments based on genetically modified cells to fight different types of cancer.Its work focuses particularly on CAR-T therapies, one of the most promising areas of precision medicine.While many conventional treatments affect healthy and tumor cells simultaneously, CAR-T therapy uses the patient’s own cells, reprogrammed to recognize and destroy cancer cells in a more targeted manner.This innovative potential is aligned with the strategic sectors prioritized by the competition, which include biomedicine and biotechnology.Furthermore, Celluris’ approach combines high-level scientific research, social impact, and potential for international scalability.
The importance of innovation in biotechnology
Biotechnology plays a central role in the transformation of modern medicine.In recent years, advances in genetic engineering, cell therapy, and immunotherapy have opened new possibilities for patients who previously had limited treatment options.In this context, innovative companies play a fundamental role in translating scientific knowledge into tangible solutions for society.Celluris operates precisely at this frontier of knowledge.Through applied research and technological development, the company seeks to make advanced therapies more accessible to Brazilian and Latin American patients.Consequently, its presence at the Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026 reinforces the international relevance of science developed in Brazil.
How the competition works
The competition follows a model designed to connect startups from Portuguese-speaking countries with the Chinese market. The process includes technical evaluation of projects, analysis of market potential, and presentations to international experts.Finalists present their solutions during pitch sessions and interact directly with investors, incubators, and research organizations.In addition to competing for awards, participants can establish commercial, technological, and scientific partnerships.Therefore, the benefits of the competition extend far beyond the financial prize.
About the opportunity
Participating in the final offers strategic opportunities for Celluris.First, the company will be able to present its technology to a highly qualified audience.In addition, it will have direct contact with investors specializing in innovation and healthcare.Another important benefit is the opportunity to connect with international research and development centers.This environment encourages collaborations that could accelerate the development of new cell therapies.At the same time, the visibility gained strengthens the company’s institutional reputation among partners, researchers, and patients.
Celluris’ mission to transform cancer treatment
Since its founding, Celluris has pursued the goal of expanding access to innovative cell therapies.The company believes that personalized medicine represents a fundamental pathway toward increasing the effectiveness of cancer treatments.For this reason, it continuously invests in research, development, and innovation.In addition, Celluris has an international structure that connects scientific knowledge, operational excellence, and strategic vision.This model enables the integration of different areas of expertise and accelerates the transfer of knowledge into future clinical applications.
The growth of CAR-T immunotherapy worldwide
CAR-T immunotherapy is transforming the treatment of different types of hematologic cancers.Several studies have demonstrated significant results in patients who did not respond adequately to conventional therapies.Consequently, governments, research centers, and investors have increased the resources allocated to the development of this technology.In this landscape, companies capable of creating innovative and scalable solutions are becoming key players in the next generation of cancer treatments.Celluris is part of this global movement.For this reason, its participation in the international competition also represents recognition of the importance of cell therapies for the future of medicine.
The impact of this achievement on Brazil’s innovation ecosystem
Celluris’ presence among the finalists has a positive impact on Brazil’s entire innovation ecosystem.International recognition helps showcase the quality of scientific research produced in Brazil.In addition, it inspires new entrepreneurs, researchers, and startups to invest in high-impact solutions.This achievement demonstrates that Brazilian companies can compete on equal terms with organizations from around the world when they combine science, technology, and strategic vision.In this way, it strengthens Brazil’s image as a producer of knowledge and innovation.
Celluris’ next steps
The next stage will be the company’s presentation in the competition final.During this process, Celluris will have the opportunity to demonstrate how its solutions can contribute to the global advancement of personalized medicine.In addition, the company will be able to expand its international network.This moment also represents an opportunity to share Brazil’s experience in cell therapy with some of the leading players in the global innovation ecosystem.Regardless of the final outcome, the selection itself already represents important recognition of the company’s journey and achievements.
Recognition: science, innovation, and commitment
Celluris’ qualification for the Macao Innovation and Entrepreneurship Competition for Technology Enterprises 2026 marks another important chapter in its history.This achievement demonstrates international recognition of the company’s work in cell therapies and CAR-T immunotherapy.In addition, it reinforces the potential of Brazilian biotechnology in one of the world’s most competitive innovation environments.By representing Brazil in this important competition, Celluris brings to the global stage a vision grounded in science, innovation, and commitment to patients.More than competing for an award, the company reaffirms its mission to transform cancer treatment through advanced and accessible technological solutions.
